Imbria Pharmaceuticals

Exciting opportunity at Imbria

Today, we announced the results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), in a late-breaking clinical trial session at ACC.24. For more info, please see our press release: https://lnkd.in/eeQVSYWu   Of note, improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated. Results support initiation of the Phase 3 FORTITUDE-HCM clinical trial of ninerafaxstat in patients with symptomatic nHCM and its continued development in heart failure with preserved ejection fraction (HFpEF). Results were published in the Journal of the American College of Cardiology (JACC). #ACC24 #cvHCM #JACC #HFpEF 

Exciting times for Imbria, please join us on Monday!

We are very much looking forward to the upcoming American College of Cardiology’s Annual Scientific Session & Expo (ACC.24) Dr. Maron will present results from the IMPROVE-HCM Phase 2 trial in a Late-Breaking Clinical Trial Session on Monday April 8th IMPROVE-HCM is evaluating ninerafaxstat, a novel cardiac mitotrope and partial fatty acid oxidation (pFOX) inhibitor, in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a large orphan disease with no approved therapies. If you are looking for details for the late-breaking clinical trial presentation, please see our press release: https://lnkd.in/dGD_mWdV #ACC24 #cvHCM

February 28 is HCM Awareness Day! Hypertrophic Cardiomyopathy (HCM) is the most common inherited cardiac and affects an estimated 1 in 500 people. HCM causes the heart muscle to become abnormally thickened and stiff. This can make it harder for the heart to relax and fill with blood, as well as limit its ability to pump blood out to the rest of the body. People with HCM can experience debilitating symptoms including breathlessness particularly during exertion, chest pain, tiredness, fainting and palpitations. At Imbria, we are fully committed to developing a new drug candidate, ninerafaxstat, that is designed to improve the heart’s ability to generate energy, with the intention to treat cardiac function in people living with the non-obstructive form of HCM and improve their lives. The Hypertrophic Cardiomyopathy Association (HCMA) provides support, advocacy, and education to patients, families, the medical community, and the public about HCM while supporting research and fostering the development of treatments.. Please visit https://4hcm.org/# to learn more about HCM, the community, and the inspiring stories of patients living with this disease. #HCMAwarenessDay #hypertrophiccardiomyopathy @4hcm #heartmonth

February 28 is HCM Awareness Day! Hypertrophic Cardiomyopathy (HCM) is the most common inherited cardiac and affects an estimated 1 in 500 people. HCM causes the heart muscle to become abnormally thickened and stiff. This can make it harder for the heart to relax and fill with blood, as well as limit its ability to pump blood out to the rest of the body. People with HCM can experience debilitating symptoms including breathlessness particularly during exertion, chest pain, tiredness, fainting and palpitations. At Imbria, we are fully committed to developing a new drug candidate, ninerafaxstat, that is designed to improve the heart’s ability to generate energy, with the intention to treat cardiac function in people living with the non-obstructive form of HCM and improve their lives. The Hypertrophic Cardiomyopathy Association (HCMA) provides support, advocacy, and education to patients, families, the medical community, and the public about HCM while supporting research and fostering the development of treatments.. Please visit https://4hcm.org/# to learn more about HCM, the community, and the inspiring stories of patients living with this disease. #HCMAwarenessDay #hypertrophiccardiomyopathy @4hcm #heartmonth

Today we announced positive topline results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a large orphan disease with no approved therapies. IMPROVE-HCM met the primary safety and efficacy trial endpoints including statistically significant improvements in exercise responses measured by standardized cardiopulmonary exercise testing as well as clinically relevant improvements in patient-reported symptoms. Based on these results we are focused on advancing ninerafaxstat into a Phase 3 clinical trial in nHCM and plan to meet with regulatory agencies to confirm trial design. Check out our PR for more info: https://lnkd.in/eBmHsuuN #cardiometabolic #hearthealth #cardiomyopathy #cardiovascular #energetics  

We are pleased to announce that we have completed enrollment in the randomized, placebo-controlled Phase 2 IMPROVE-ISCHEMIA clinical trial of ninerafaxstat in patients with stable angina. IMPROVE-ISCHEMIA is designed to evaluate the anti-ischemic effects of ninerafaxstat in symptomatic patients with chronic coronary syndromes, including angina – an area of pressing need given the limited level of therapeutic innovation and high symptomatic burden. Looking forward to reporting topline data for this study, as well as additional Phase 2 data read-outs for the IMPROVE-HCM in non-obstructive hypertrophic cardiomyopathy and interim data from IMPROVE-DiCE in cardiometabolic heart failure with preserved ejection fraction (HFpEF) - all coming up in 4Q 2023! Check out our PR for more info: https://lnkd.in/eSj-Cnt9 #cardiometabolicdisorders #hearthealth #angina #ischemia #cardiomyopathy